Anti-Coagulants - Spain

Spain

In Spain, the revenue in the Anti-Coagulants market is forecasted to reach €402.30m by 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 6.87%, leading to a market volume of €560.70m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Coagulants market, amounting to €15,360.00m in 2024.
Spain's anti-coagulant market is experiencing a surge in demand due to the aging population and the increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Coagulants market in Spain has been experiencing steady growth in recent years.

Customer preferences: Patients in Spain are increasingly opting for novel oral anticoagulants (NOACs) over traditional anticoagulants such as warfarin. This is due to the fact that NOACs have a lower risk of bleeding and do not require frequent monitoring like warfarin. Additionally, NOACs have a faster onset of action and a shorter half-life, which makes them more convenient for patients.

Trends in the market: The Anti-Coagulants market in Spain has been growing due to an increase in the prevalence of atrial fibrillation and other cardiovascular diseases. As the population ages, the incidence of these diseases is expected to rise, which will drive demand for anti-coagulants. Additionally, the market is expected to continue to shift towards NOACs as more patients become aware of their benefits.

Local special circumstances: One of the unique factors in the Spanish market is the high level of generic competition. This has led to lower prices for anti-coagulants, which has made them more accessible to patients. Additionally, the Spanish government has implemented policies to encourage the use of generic drugs, which has further driven down prices.

Underlying macroeconomic factors: Spain has been recovering from a period of economic instability, which has led to an increase in healthcare spending. This has allowed for greater access to anti-coagulants for patients. Additionally, the Spanish government has implemented policies to encourage the use of generic drugs, which has further driven down prices. Overall, the combination of an aging population, an increase in the prevalence of cardiovascular diseases, and greater access to healthcare has led to steady growth in the Anti-Coagulants market in Spain.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.